Ab­b­Vie's Gon­za­lez: Skyrizi and Rin­voq to be­come Hu­mi­ra 2.0 — while adding an in­di­ca­tion for atopic der­mati­tis

While Ab­b­Vie’s Hu­mi­ra still holds the crown for the best-sell­ing non-Covid drug last year, the Big Phar­ma has its eyes on Hu­mi­ra’s po­ten­tial suc­ces­sor. Scratch that, suc­ces­sors.

Ab­b­Vie CEO Rick Gon­za­lez told in­vestors and an­a­lysts on the phar­ma’s Q4 call this morn­ing that Ab­b­Vie ex­pects to add sev­er­al new in­di­ca­tions to Skyrizi and Rin­voq’s “list of ap­proved us­es” over the next few months. For Skyrizi, they got the FDA’s OK a few weeks ago to use the drug for pso­ri­at­ic arthri­tis — and they’re al­so look­ing for the thumbs up from the agency on Crohn’s dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER